

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

HuH-6

RRID:CVCL_4381

Type: Cell Line

Proper Citation

RRID:CVCL_4381

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4381

Proper Citation: RRID:CVCL_4381

Description: Cell line HuH-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:57894](#), [PMID:8389256](#), [PMID:9359923](#), [PMID:9671767](#), [PMID:15767549](#), [PMID:20937217](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32899426](#)

Comments: Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuH-6

Synonyms: HUH-6, HuH 6, HuH6, HUH6, Huh6

Cross References: BTO:BTO_0001670, CLO:CLO_0050851, ABM:T9914, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:643, BioSample:SAMN10987713, cancercellines:CVCL_4381, CCRID:1101HUM-PUMC000477, CCRID:3101HUMTCHu181, Cell_Model_Passport:SIDM00062, CLS:305092, Cosmic:869168, Cosmic:869279, Cosmic:873714, Cosmic:1187329, Cosmic:1237546, Cosmic:1518228, Cosmic:1622750, Cosmic:2162537, Cosmic:2369478, Cosmic:2771602, DepMap:ACH-000671, FANTOM5_SSTAR:10633-10813,

GEO:GSM887148, GEO:GSM888220, GEO:GSM936762, IARC_TP53:28317, LiGeA:CCLE_149, Progenetix:CVCL_4381, RCB:RCB1367, Wikidata:Q54896848

ID: CVCL_4381

Record Creation Time: 20220427T220622+0000

Record Last Update: 20260829T234255+0000

Ratings and Alerts

No rating or validation information has been found for HuH-6.

No alerts have been found for HuH-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 212 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. HGG advances, 7(3), 100630.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. Molecular cell.

Daniel Y, et al. (2025) PPAR?, a key modulator of metabolic reprogramming, stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas. Cell death & disease, 16(1), 831.

Rodemann MM, et al. (2025) Identification of a Growth-Promoting Gene Cluster in the Region 2q24 as a Driver of Tumorigenesis in Childhood Hepatoblastoma. The American journal of pathology, 195(8), 1553.

Gritti I, et al. (2025) DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming. Cancer discovery, 15(2), 382.

Pérez-Chávez I, et al. (2024) Tracking fructose 1,6-bisphosphate dynamics in liver cancer cells using a fluorescent biosensor. iScience, 27(12), 111336.

Song M, et al. (2024) DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma. Cancer research, 84(10), 1613.

Guo T, et al. (2023) Dihydromyricetin functions as a tumor suppressor in hepatoblastoma by regulating SOD1/ROS pathway. *Frontiers in oncology*, 13, 1160548.

Kong Y, et al. (2023) Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation. *Redox biology*, 63, 102732.

Zhu J, et al. (2023) SNORA14A inhibits hepatoblastoma cell proliferation by regulating SDHB-mediated succinate metabolism. *Cell death discovery*, 9(1), 36.

Héraud C, et al. (2023) Identification of an inhibitory domain in GTPase-activating protein p190RhoGAP responsible for masking its functional GAP domain. *The Journal of biological chemistry*, 299(1), 102792.

Zhou Y, et al. (2023) Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. *EBioMedicine*, 87, 104397.

Gest C, et al. (2023) Antagonism between wild-type and mutant β -catenin controls hepatoblastoma differentiation via fascin-1. *JHEP reports : innovation in hepatology*, 5(5), 100691.

Tang Y, et al. (2023) β -catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. *Cell communication and signaling : CCS*, 21(1), 162.

Cui Z, et al. (2023) O-GlcNAcylated LARP1 positively regulated by circCLNS1A facilitates hepatoblastoma progression through DKK4/ β -catenin signalling. *Clinical and translational medicine*, 13(4), e1239.

Nousiainen R, et al. (2023) UBE2C expression is elevated in hepatoblastoma and correlates with inferior patient survival. *Frontiers in genetics*, 14, 1170940.

Tsuchiya H, et al. (2023) NEAT1-SOD2 Axis Confers Sorafenib and Lenvatinib Resistance by Activating AKT in Liver Cancer Cell Lines. *Current issues in molecular biology*, 45(2), 1073.

Chen DY, et al. (2023) Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. *iScience*, 26(5), 106634.

Han Y, et al. (2023) BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. *Clinical and translational medicine*, 13(5), e1247.

Eloranta K, et al. (2023) SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration. *Frontiers in oncology*, 13, 1118268.